NASDAQ:OPTN OptiNose (OPTN) Stock Price, News & Analysis $1.11 +0.03 (+2.78%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.08▼$1.1250-Day Range$1.00▼$1.2752-Week Range$0.80▼$2.10Volume156,527 shsAverage Volume869,611 shsMarket Capitalization$125.47 millionP/E RatioN/ADividend YieldN/APrice Target$3.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends Get OptiNose alerts: Email Address OptiNose MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside230.3% Upside$3.67 Price TargetShort InterestHealthy5.04% of Shares Sold ShortDividend StrengthN/ASustainability-2.10Upright™ Environmental ScoreNews Sentiment0.87Based on 2 Articles This WeekInsider TradingSelling Shares$217,636 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.26) to ($0.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.42 out of 5 starsMedical Sector130th out of 936 stocksPharmaceutical Preparations Industry50th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingOptiNose has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOptiNose has only been the subject of 2 research reports in the past 90 days.Read more about OptiNose's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.04% of the outstanding shares of OptiNose have been sold short.Short Interest Ratio / Days to CoverOptiNose has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in OptiNose has recently decreased by 26.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOptiNose does not currently pay a dividend.Dividend GrowthOptiNose does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOptiNose has received a 60.30% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sumatriptan", "Nasal medication (R01)", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for OptiNose is -2.10. Previous Next 3.3 News and Social Media Coverage News SentimentOptiNose has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for OptiNose this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for OPTN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added OptiNose to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OptiNose insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $217,636.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of OptiNose is held by insiders.Percentage Held by Institutions85.60% of the stock of OptiNose is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OptiNose's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OptiNose are expected to grow in the coming year, from ($0.26) to ($0.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptiNose is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptiNose is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about OptiNose's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.I have uncovered a bombshell that changes everything… and threatens everything. About OptiNose Stock (NASDAQ:OPTN)OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.Read More OPTN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPTN Stock News HeadlinesJuly 19, 2024 | insidertrades.comInsider Selling: OptiNose, Inc. (NASDAQ:OPTN) Insider Sells 49,408 Shares of StockJuly 19, 2024 | americanbankingnews.comOptiNose, Inc. (NASDAQ:OPTN) CEO Ramy A. Mahmoud Sells 111,426 SharesJuly 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."July 19, 2024 | americanbankingnews.comOptiNose, Inc. (NASDAQ:OPTN) Insider Michael F. Marino III Sells 49,408 SharesJune 27, 2024 | globenewswire.comExpanded Access to XHANCE with Addition to National Commercial FormulariesMay 19, 2024 | msn.comOptiNose, Inc. (NASDAQ:OPTN) Q1 2024 Earnings Call TranscriptMay 17, 2024 | msn.comOptinose to Provide Business Update at H.C. Wainwright ConferenceMay 17, 2024 | globenewswire.comOptinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQJuly 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."May 15, 2024 | markets.businessinsider.comOptinose’s XHANCE Expansion Drives Buy Rating Amidst Growth PotentialMay 15, 2024 | msn.comOptinose Reports Growth in Q1 and Optimistic Outlook for XHANCEMay 15, 2024 | finance.yahoo.comOptiNose Inc (OPTN) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Financial ...May 14, 2024 | investorplace.comOPTN Stock Earnings: OptiNose Misses EPS, Beats Revenue for Q1 2024May 14, 2024 | finance.yahoo.comOptinose Reports First Quarter 2024 Financial Results and Recent Operational HighlightsMay 14, 2024 | globenewswire.comOptinose Reports First Quarter 2024 Financial Results and Recent Operational HighlightsMay 13, 2024 | ca.finance.yahoo.comOptiNose, Inc. (OPTN) Stock Price, News, Quote & History - Yahoo FinanceMay 12, 2024 | msn.comOptinose to Unveil First Quarter 2024 Financial Results and UpdatesMay 10, 2024 | finance.yahoo.comOptiNose Inc (OPTN) Announces $55 Million Financing Round Amidst Revenue ProjectionsSee More Headlines Receive OPTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OPTN CUSIPN/A CIK1494650 Webwww.optinose.com Phone(267) 364-3500FaxN/AEmployees132Year FoundedN/APrice Target and Rating Average Stock Price Target$3.67 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+233.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,480,000.00 Net Margins-41.55% Pretax Margin-41.48% Return on EquityN/A Return on Assets-30.84% Debt Debt-to-Equity RatioN/A Current Ratio2.48 Quick Ratio2.17 Sales & Book Value Annual Sales$70.99 million Price / Sales1.75 Cash FlowN/A Price / Cash FlowN/A Book Value($0.77) per share Price / Book-1.43Miscellaneous Outstanding Shares113,040,000Free Float109,987,000Market Cap$124.34 million OptionableNot Optionable Beta-0.12 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Ramy A. Mahmoud M.D. (Age 59)M.P.H., CEO & Director Comp: $1.12MMr. Michael F. Marino Esq. (Age 48)Chief Legal Officer & Corporate Secretary Comp: $785.95kMr. Paul Spence (Age 55)Chief Commercial Officer Comp: $664.02kMr. Anthony J. Krick (Age 43)VP of Finance & Chief Accounting Officer Mr. Jonathan NeelyVice President of Investor Relations & Business DevelopmentMs. Karen E. Brophy (Age 61)Chief Human Resources Officer & VP of Human Resources More ExecutivesKey CompetitorsVeruNASDAQ:VERUscPharmaceuticalsNASDAQ:SCPHChiasmaNASDAQ:CHMAOculisNASDAQ:OCSTheravance BiopharmaNASDAQ:TBPHView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 173,952 shares on 7/26/2024Ownership: 0.162%Easterly Investment Partners LLCBought 208,185 shares on 7/25/2024Ownership: 1.987%Assenagon Asset Management S.A.Sold 10,911 shares on 7/18/2024Ownership: 0.067%Ramy A MahmoudSold 111,426 sharesTotal: $127,025.64 ($1.14/share)Michael F Marino IIISold 49,408 sharesTotal: $56,325.12 ($1.14/share)View All Insider TransactionsView All Institutional Transactions OPTN Stock Analysis - Frequently Asked Questions How have OPTN shares performed this year? OptiNose's stock was trading at $1.29 at the beginning of 2024. Since then, OPTN stock has decreased by 14.0% and is now trading at $1.11. View the best growth stocks for 2024 here. How were OptiNose's earnings last quarter? OptiNose, Inc. (NASDAQ:OPTN) issued its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.02. The company earned $14.88 million during the quarter, compared to the consensus estimate of $13.95 million. When did OptiNose IPO? OptiNose (OPTN) raised $101 million in an initial public offering on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO. Who are OptiNose's major shareholders? Top institutional shareholders of OptiNose include Rosalind Advisors Inc. (6.68%), Easterly Investment Partners LLC (1.99%), Bank of New York Mellon Corp (0.16%) and Assenagon Asset Management S.A. (0.07%). Insiders that own company stock include Ramy A Mahmoud, Peter K Miller, Michael F Marino III, Anthony J Krick, Michele Janis, Victor M Clavelli and Keith A Goldan. View institutional ownership trends. How do I buy shares of OptiNose? Shares of OPTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of OptiNose own? Based on aggregate information from My MarketBeat watchlists, some other companies that OptiNose investors own include Proteostasis Therapeutics (PTI), Idera Pharmaceuticals (IDRA), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB) and Selecta Biosciences (SELB). This page (NASDAQ:OPTN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptiNose, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptiNose With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPTN Stock Alerts